Peter Chambré

Bain & Co., Inc. provides management consulting services. It offers advisory services to the companies on their critical issues and opportunities: strategy, marketing, organization, operations, technology and mergers and acquisitions, across all industries and geographies. The company was founded in 1973 and is headquartered in Boston, MA.

Celera Group provides molecular diagnostics using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers and to develop diagnostic products based on these markers. These diagnostic products are used to predict disease risk and optimize therapy selection, monitoring and patient outcome. The company was founded in May, 1998 and is located in Rockville, MD

ApaTech Ltd. develops synthetic bone graft technology. It specializes in producing synthetic bone repair material. The company has developed a novel silicate substituted calcium phosphate bone graft material, Actifuse, which underpins the company's leadership in applying the science of silicon to bone graft technologies. Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive, osteostimulatory and bioactive qualities resulting in accelerated bone growth. The company was founded in 2001 and is headquartered in Elstree, UK.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom.

7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark.

Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom.

Xellia Pharmaceuticals AS develops, manufactures, and supplies pharmaceutical drugs. The firm engages in the filed of biotechnology, synthetic organic chemistry development, and analytical development. The company was founded in 1946 and is headquartered in Oslo, Norway.

OneMed AB distributes consumable medical products, devices, and technology in the healthcare industry. It also supplements its product range with services within purchasing, logistics, administration, information technology, support, education, product range planning, ordering procedures, as well as providing know-how on healthcare consequences and product management. Its product portfolio consists of products evercare, SELEFA, and BATIST. The firm offers Gloves; Surgical drapes, sets and gowns; Minor procedure sets; Protective apparel; Surgical masks and caps; Wound care and bandages; Paper and plastic protection; and Consumables. The company was founded in 2006 and is headquartered in Danderyd, Sweden.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

Part of AstraZeneca PLC, Cambridge Antibody Technology Group Ltd. is a holding company that oversees its subsidiaries' research, development, and exploitation of molecular engineering products. The company is based in Cambridge, UK and was founded in 1996.

Our Future Health UK is a collaboration between the public, private, and charity sectors. Our Future Health UK is a member of the UK Health Data Research Alliance, which establishes best practices for the ethical use of UK health data for research at scale. The private company is based in Manchester, UK. The British company aims to be the largest health research program in the UK, bringing people together to develop new ways to prevent, detect, and treat diseases. The company is committed to protecting participants' confidentiality while maximizing the opportunity to help researchers tackle serious diseases. The CEO of the company is Andrew Roddam.